EVLO
- Evelo Biosciences, Inc.
()
Overview
Company Summary
Evelo Biosciences, Inc. is a biotechnology company focused on the development of therapies for various diseases by harnessing the potential of the gut-body network. The company specializes in the field of monoclonal microbials, an emerging therapeutic modality that aims to modulate the interactions between the gut and other organs in the body to address various illnesses.
Evelo's approach is based on the understanding that the gut, comprising trillions of microbes, plays a crucial role in regulating the immune system and overall health. By developing oral biologics, Evelo aims to modulate the gut-body network and potentially treat a range of diseases, including autoimmune, inflammatory, and metabolic disorders.
The company has developed a proprietary platform called Microbiome-Derived Molecular Entities (MMEs). These MMEs consist of naturally occurring microbes, specifically selected or modified to produce specific therapeutic effects. Evelo's platform enables the identification of specific microbial strains and their metabolites that could positively impact disease conditions.
Evelo is conducting research and development programs across several therapeutic areas, including oncology, immunology, and inflammatory diseases. For example, in oncology, the company is investigating the potential of MMEs to enhance the efficacy of existing cancer immunotherapies.
As of now, Evelo Biosciences is primarily focused on preclinical and early-stage clinical development, conducting research and trials to demonstrate therapeutic potential and safety of its products. If successful, their approach could bring about a new class of therapies that target diseases by leveraging the intricate interactions of the gut microbiome with the rest of the body.